MicroRNA-27a Suppresses the Toxic Action of Mepivacaine on Breast Cancer Cells via Inositol-Requiring Enzyme 1-TNF Receptor-Associated Factor 2.

OBJECTIVE: To investigate the toxic effects of microRNA-27a on breast cancer cells through inositol-acquiring enzyme 1-TNF receptor-associated factor 2 inhibition by mepivacaine.

METHODS: The elevation of miR-27a in MCF-7 of BCC lines was measured, and groups were set up as control, mepivacaine, and elevated groups. Cells from each group were examined for inflammatory progression.

RESULTS: Elevated miR-27a in MCF-7 cells was able to distinctly augment the cell advancement ( P < 0.01) and decline cell progression ( P < 0.01). Meanwhile, miR-27a reduced the content of intracellular inflammatory factors IL-1 β ( P < 0.01) and IL-6 ( P < 0.01), elevated the content of IL-10 ( P < 0.01), suppressed levels of cleaved-caspase-3 and p-signal transducer and activator of transcription-3 (STAT3) ( P < 0.01), and increased Bcl-2/Bax ( P < 0.01).

CONCLUSION: Elevated miR-27a in MCF-7 of BCC lineage was effective in reducing the toxic effects of mepivacaine on cells and enhancing cell progression. This mechanism is thought to be related to the activation of the IRE1-TRAF2 signaling pathway in BCC. The findings may provide a theoretical basis for targeted treatment of BC in clinical practice.